Rosacea | A Drug Pipeline Analysis Report 2018| Technavio

Technavio has published a new report on the drug development pipeline for rosacea, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest drug pipeline analysis report on rosacea. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat rosacea.

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Rosacea: Market overview

Rosacea is a commonly occurring skin condition that is mistaken for acne, an allergic reaction, or any other skin problems. This skin condition can be aggravated by factors such as alcohol, extreme temperature, sunlight, wind, emotions, hot drinks, spicy food, cosmetics, and drugs prescribed to dilate blood vessels. This disorder has numerous symptoms such as facial redness, swollen red bumps, eye problems, and enlarged nose.

According to a senior market research analyst at Technavio, “The National Institutes of Arthritis and Musculoskeletal and Skin Diseases stated in their research that rosacea can occur to any individual; however, it is prevalent in adults aged 30 to 60 years, women during menopause condition, and people with fair skin.”

Rosacea: Segmentation analysis

This pipeline analysis report segments the rosacea market based on therapies employed (monotherapy), RoA (topical and oral), therapeutic modality (small molecule, biological, and peptides), targets (30S ribosomal subunit, 14-alpha-demethylase, ammonia, keratinocyte, proteasome, serine protease, toll-like receptor (TLR), and TRPV1 receptor), MoA (Protein 30S ribosomal subunit inhibitors, 14-alpha-demethylase inhibitors, cell membrane permeability enhancers, keratinocyte inhibitors, nitric oxide donor, proteasome inhibitors, serine protease inhibitors, TLR modulator, and TRPV1 receptor antagonists), geographical segmentation (US, Germany, UK, the Netherlands, Australia, Canada, France, New Zealand, Sweden, and South Korea) and recruitment status (active, not recruiting, completed, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, more than 73% of the molecules that are being investigated for the treatment of rosacea are small molecules.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

Technavio has published a new report on the drug development pipeline for rosacea, including a detailed study of the pipeline molecules.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com